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RASSF1A is a tumor suppressor gene which loses its function due to
methylation of CpG islands on its promoter region. Detection of methylation leads to
early diagnosis of cancer.
Zinc finger proteins are capable of detecting a specific DNA sequence and
Methyl binding domain can bind to the methyl group on the CpG, using this idea
mCpG SEER- Lac system makes use of a split protein, -lactamase. Lac A attached to
the ZFP and Lac B attached to the MBD protein. On binding to the DNA, the Lac A
and Lac B come in close proximity with each other causing a reassembly and
activation of the enzyme. In the presence of a substrate, the activated -lactamse
enzyme hydrolyzes the -lactam bond in the substrate and shows a color change from
yellow to red in the presence of a methylated cognate DNA.
The study suggests that a solution based assay was not as specific in
differentiating signal intensities between methylated and non-methylated DNA. It was
also not sensitive in measuring dose dependent signals. Zinc finger array could
successfully show relatively low signals for non-methylated DNA. The findings of the
study show that MBD2 shows higher preference for mCpG than MBD1 in the mCpG
SEER-Lac system and oligonucleotides with a 2 bp spacing between methylation and
ZF target site shows higher signals than the 3 bp spacing. Due to it’s specificity and
sensitivity, it serves as a potential diagnostic tool to detect cancer.
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CHAPTER 1
LITERATURE AND INTRODUCTION
1. RASSF1A gene
Carcinogenesis is a result of malfunction in various processes involving different
regulators and factors. Proteins encoded by tumor suppressor gene (TSG) are involved
in inhibition of cell survival and growth. Hence, silencing of a TSG due to mutation
can result in the inhibition of these negative regulatory proteins. Studying these genes
may provide more information about the cancer and help in early diagnosis. TSGs
regulate the rate of proliferation and apoptosis (1). TSGs prevent proto-oncogenes
from turning into oncogenes due to any mutagenesis.
Ras association domain family (RASSF) is a TSG and a part of the Ras family
proteins, which are ubiquitously expressed in all cell lines (2,3). Ras proteins in
normal conditions are associated with oncogenic effects such as decreased cell death
and increased cell proliferation (3). Epigenetic modifications cause changes in the
RASSF1A gene due to external factors without changing the DNA sequence.
Epigenetic inactivation of RASSF1A due to a process where unusual number of CG
dinucleotides get methylted, called hypermethyaltion on the promoter region causes
inactivation of the gene (4). Silencing of RASSF1A may be correlated with activation
of Ras effectors in the Ras-dependent tumors. The major Ras effectors are K-ras, Hras and N-ras (5).
Currently, the RASSF consists of 10 members. The functions of few are known
distinctly. RASSF1 is a member of six related proteins and contain multiple splice
variants. Each protein contains Ras associated domain and a C-terminal SARAH
(sav/RASSF/Hpo) protein-protein interaction (5). Another member of the RASSF
family, RASSF2 plays a major role in cell apoptosis and it is also seen to be down
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regulated in tumors due to methylation, histone deacetylation and deletion of the gene.
It was proven that reintroduction after deletion hindered and deletion enhanced the
process of tumor genesis (6). RASSF3 can bind to Ras and inhibit cell growth, but it
is not downregulated in tumors. The involvement of RASSF3 in cancer remains
unknown (7). RASSF4 also binds to Ras and induces cell apoptosis (4). RASSF5 was
initially called Nore1a and was the first family to be cloned (8). It is pro-apoptotic and
stops cell growth through the Ras mediated pathway (9). It is very often inactivated in
human tumors due to promoter methylation. It may regulate the pro-apoptotic kinase
MST1 in the Ras mediated pathway (10). RASSF5 can also form a complex with the
Ras related protein (Rap). which regulates lymphocyte adhesion and acts as a TSG
(11). RASSF6 possesses similar biological properties. It is frequently downregulated
in tumors (12) and its location is suggested to be involved in bronchiolitis inflected by
respiratory syncytial virus (13). Two other identified Ras association domain proteins
are RASSF7 and RASSF8. They do not display homology with RASSF1 through 6
(14).
Table 1: Summary of Ras association domain family members and their functions
(4,6,7,12)
Member

Function

RASSF1 (Isoforms A-G)

Activation of cell death, cell cycle, and microtubule
formation

RASSF2

Apoptosis via cell cycle arrest

RASSF3

Binds to Ras to inhibit cell growth

RASSF5

Pro-apoptotic and kills cells in a Ras dependent manner

RASSF6

Promotes apoptosis to induce cell death and tumor cell
survival.
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1.1 Locus and Gene description

Figure 1: The promoters of RASSF1 are located in the CpG islands (hollow
rectangles). Three major isoforms are RASSF1A, RASSF1C and RASSF1F and
encompass a different combination of the exons 3,4,5 and, 6 remain common for all
isoforms (15).
The gene locus of RASSF1 spans about 11,151 bp of the human genome. It
contains eight different exons and alternative splicing gives rise to two different
promoters 3.5 kb apart (16). Alternative splicing yields 7 transcripts (A-G). Isoforms
A and C are ubiquitously expressed and isoform B is expressed in the cells of
hemopoietic system. Isoform D and E are produced in cardiac and pancreatic cells
respectively. There are two CpG islands associated with RASSF1 promoters. The
smaller promoter of the two comprises of 737 bp which encompasses 85 CpGs and is
observed in RASSF1D, RASSF1E, RASSF1F and RASSF1G. The second larger CpG
island spans 1,365 bp and encompasses 139 CpGs which is encoded in RASSF1B and
RASSF1C (16).
RASSF1A encompasses the smaller CpG island 1 and spans one of the two
exons of the larger CpG island 2 β and the last four exons remain common for all
isoforms. The Ras association domain encoded by exons 4 and 5 defines the RASSF1
3

gene and is located at the C-terminus of isoforms A-E. This domain is involved in
interactions of Ras and other GTPases. The Ras association domain is composed of
five-stranded mixed β-sheets and three -helices. These domains dimerize by
intermolecular disulfide bonds formed between the cysteine residues from each
monomer. RASSF1A and RASSF1D-G have a N-terminal protein kinase conserved
region called C1 domain encoded by exons 1  and 1 . This is the diacylglycerol
binding domain (DAG) that is responsible for regulating activity of kinase.
Overlapping the C1 region, is the zinc finger binding domain ZNF-NFX. A SARAH
domain (sav/RASSF/Hpo) is present at the C-terminus of RASSF1A-E. These
domains mediate interactions between proteins for Hpo/Sav homotypic interactions
with MST1 (16).
1.2 Biological role of RASSF1A

Figure 2: Pathways used by RASSF1A in different biological functions (17).
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1.2.1 Deregulating microtubule dynamics
Polymers of tubulin, called as microtubules are capable of assembling and
disassembling at various stages of cell cycle. Their function is to ensure segregation
of sister chromatid and regulate cytokinesis (18). Microtubule associated protein
(MAP) binds directly to tubulin. RASSF1A could be associated with microtubules by
mediating MAPs. MAP1b promotes polymerization of microtubules. Microtubules
can switch between stages of elongation and shortening; this process is called as
dynamic instability. Stabilizing the microtubule causes loss of its function. RASSF1A
is localized to the microtubules and promotes its stabilization (5).
1.2.2 Cyclin dependent deregulation of cell cycle
c-Jun-NH2-Kinase is also called stress-activate protein kinase (SAPK). It has the
ability to phosphorylate the N-terminal of transcription factor, c-Jun, activating it as a
response to various stress. JNK is involved in multiple pathways and is an important
mediator in the process of cell death. One of its many pathways involve Ras effectors
proteins. Overexpression of RASSF1A suppresses Ras induced phosphorylation of
(JNK) c-Jun-NH2-Kinase, which in turn decreases the levels of cyclin D1(19). Cyclin
D1 is an essential factor required by the cells for progression of cell cycle through the
Rb checkpoint . RASSF1A induced decrease in JNK signaling and cyclin D1 levels
causes cell cycle arrest in the G1 phase of the cycle (20).
1.2.3 Cell apoptosis
Mammalian sterile 20 like kinase, MST1 and MST2 are pro-apoptotic serine
and threonine kinases that activate JNK pathway in a way discussed earlier. MST1
helps RASSF1A to phosphorylate histone, which causes condensation of chromatin
and apoptosis due to lack of transcriptional control (5).
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A scaffold protein called CNK1 augments RASSF1A induced cell death. This
is a connector enhancer of KSR (CNK) and a c-Raf1 binding protein which is a
mediator of Ras induced Raf activation. CNK1- RASSF1A surpasses the growth
cancer cells via MST1 leading to apoptosis by the pro-apoptotic MST1 pathway (21).
Modulator of apoptosis (MOAP1) is another pro-apoptotic protein, it get’s
activated by stimulation of death receptors and arms (tumor necrosis factor receptor)
TNFR-MOADP1 complex, localizing RASSF1A to the death receptor (22). This
complex also activates another pre-apoptotic protein called bcl-2-like protein 4 (Bax)
and p21, which is called cyclin dependent kinase inhibitor 1. RASSF1A-MOAP1
initiates a conformational change in MOAP1, exposing its hidden BH3-like domain
and enabling it to interact with Bax. In this way, Bax inserts itself into the
mitochondrial membrane and executes cell apoptosis. This interaction is dramatically
amplified by activated K-Ras and absence of RASSF1A intervenes with the ability of
K-Ras to activate Bax. Thus a Ras-RASSF1A-MOAP1 complex is important for Ras
induced cell apoptosis (22).
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1.3 Methylation of RASSF1A
DNA methyltransferase (DNMT) is an enzyme responsible for modifying one
position in the target DNA sequence. In humans, the DNMT falsely recognizes the
DNA sequence and methylates the cytosine in CpG rich areas. Sequences that may get
methylated are exons, introns, repetitive regions in the DNA, regulatory elements, and
other transposons (23). DNMT catalyzes the transfer of a methyl group from a Sadenosyl-L-methionine to cytosine of a hemimethylated DNA (24). Promoter based
aberrant hypermethylation of tumor suppressor genes along with hypomethylation is
associated with high rates of mutagenesis and it is an essential factor in the process of
carcinogenesis. This suggests that methylation of DNA is an important function in the
genetic integrity system (25). When DNMT methylates a DNA sequence, it recruits
histone deacetylases from the neighboring region of the DNA, repressing transcription
of the gene (26).
Gene silencing of tumor suppressor gene RASSF1A, is a fundamental
epigenetic inactivation mechanism of genes related to cancer (27). In case of
RASSF1A, promoter hypermethylation is a most common inactivation process which
causes loss of functionality of the gene (21). Aberrant tumor hypermethylation of
RASSF1A was detected in several tumors like breast, lungs, colon, kidney, prostate
and bladder cancer (28). The cytosine on the CpG islands in the promoter region of
the gene is methylated on an account of epigenetic inactivation. This causes failure of
RASSF1A gene to disrupt the cell cycle allowing uncontrolled growth of cells.
Detection of methylated DNA was correlated to availability of methylated tumorderived DNA and detection of non-methylated DNA suggested absence of cancer
(29). Unlike proteins, DNA may be amplified to a certain extent, this fact gave
researchers an advantage to detect methylated DNA. For a long period of time,
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methylated tumor-derived DNA has been known to be available in the blood stream
(30). It was later studied that methylated RASSF1A was also found in other body
fluids corresponding to the tumor of that tissue (30,31)

Figure 3: A bar graph indicating percentage frequency of methylation of RASSF1A in
different tumors (21).
A study conducted by Yihao et al. suggests that RASSF1A gets
hypermethylated in a CG rich region (32). They showed that methylated RASSF1A
lacks a TATA box CG region which is essential for transcription initiation by the
RNA polymerase 2 complex. This was consistent over short distances like 250 bp,
and was observed to be a common trait of active promoters. The methylated DNA
after treatment with bisulfite facilitates the conversion of methyl cytosine to uracil,
which is amplified using real-time PCR and sequenced. Their results in bisulfite
sequencing of RASSF1A CpG islands showed 78.5% of the GC sites which were
methylated in testicular tumor (30).
Some studies conducted by Wei Meng suggests that RASSF2A also get
hypermethylated in carcinomas (14). And it concluded that RASSF1A was
methylated in 68% and RASSF2A in 7% of transitional cell carcinoma. Hence it can
be concluded that RASSF1A is a more dependable biomarker than RASSF2A. This
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study indicated that detection of promoter methylation in urine specimen together
showed good sensitivity (77%) and high specify (94%) identifying bladder cancer
tissues (14).

Figure 4: Methylation in RASSF1A as compared to RASSF2A (32).
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2. DNA Binding domain
DNA-binding Proteins can “read” nucleotide sequences because of two
suitable conditions (33). First being the B form of DNA, present in most cell
population, has base pairing from one phosphate backbone to another. The number
of hydrogen bonds and the final structure that forms due to the hydrogen bonds (A
forms two bond with T and G forms a three bond with C) helps DNA-binding
proteins to distinguish between different nucleotide bases. The methyl group on
the thymine is a sequence recognition element that encourages the DNA
recognition process. Second being the ability to accommodate the DNA binding
protein. The major groove of the DNA is larger in area than the minor groove and
can easily accommodate the helical structure of the protein. Hence, the nucleotides
on the exterior face of the helix should be able to read and recognize target
nucleotide sequences without disruption in the sequence of the DNA’s initial
structure.
2.1 Zinc finger proteins (ZFPs)
The Cys2-His2 is the most common type of zinc finger (ZF) and is the first
member of the extensively expanding group of the zinc-binding modules. They are
one of the most abundantly expressed proteins in the eukaryotic cell (34). The
function of a ZFwas reported in 1989, since then the structures of all its complexes
have been discovered starting with Zif268. Wright et. al (35) defined ZFs to be
small, functional, independently folded domain coordinated with one or more zinc
molecules in order the structure. The most frequently used is the one where the
amino acids form a ββα framework (36). These folds are stabilized by the
hydrophobic coordination network of the Zn and this framework provides an
insight to how the ZFP interact with the DNA. Twenty-five of the 30 amino acids
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in the repeat, fold around the zinc to form a ‘finger’ and the rest of the five amino
acids serve as linkers between consecutive fingers. The zinc ion forms a
tetrahedral complex coordinated to two pairs of cysteine and histidine. This
hydrophobic interaction of the coordination network between the Zn and the
cysteine and histidine residues stabilize the fingers (37). The amino acids in each
ZF have the affinity with specific nucleotides. Therefore, every finger is capable
of specifically and selectively recognizing 3-4 nucleotides of the DNA (34).
Multiple ZF can be arranged into tandem arrays and can recognize a set of
nucleotides on the DNA. Using methods like combinatorial mutagenesis, where in,
a large number of mutants are screened for DNA specificity (38), it is possible to
create modules of six zinc fingers that can potentially recognize 18 bp. The length
of 18 bp would be long enough for ZFPs to recognize any desired DNA sequence
in the human genome. In Zif268 a canonical type of screening to recognize the
nucleotide sequence was observed (34). The amino acids in positions -1, 3, 6
contact the 3’, middle, 5’ nucleotides respectively. Different ZF DNA binding
proteins may be engineered to bind to unique DNA sequnces (39).

Figure 5 Structure of a ZFP showing zinc ion in the center (grey circle) forming coordinate bonds with two Cys and two His residues, showing ββα framework. (34)
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In principle, multi-finger proteins in modular assembly, can be constructed
by assembling predefined ZF modules in any order to recognize any desired DNA
sequences in a modular fashion (40). A scarcely occurring hindrance in
recognition pattern for modular assembly is called “context-dependent effect”
(40). For example, due to this effect, if the amino acid on the α-helix is an
Aspartate, then it recognizes the guanine or thymine on the subsite of the previous
ZF, when they happen to be the first nucleotide in the subsite. This is due to the
helical nature of the amino acid and is called target site overlap (TSO). Other
types of context-dependent effects may be the result of sequence irregularities in
the DNA structure due to base stacking. Recognition of this effect led to the
development of second generation ZFPs that would have higher selectivity for
longer sequences (40).
2.2 Modular assembly and construction of ZFPs
Each ZF recognizes 3 bp of DNA, which seems to be simple mode of DNA
recognition. This may inspire creation of multi-finger proteins that can recognize
any extended DNA sequences. Multiple approaches have been taken to identify
optimized individual ZF modules to recognize one of the 64 possible 3 bp DNA
subsites, using combination of rational design and selection (40). However, there
are other ways to assemble ZFs. For example, Carroll et. al (41) used a PCR based
method to construct multi-finger proteins. Wright et. al (42) developed an archive
of plasmids encoding more that 140 ZF modules along with a complementary
web-based software called ZiFiT to verify potential ZF targets on the gene of
interest.
The Barbas and ToolGen domains are the two most commonly used sets of
modular assembly fingers. Both domains cover 3 bp GNN, most ANN, many
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CNN and some TNN triplets (where N can be any of the four nucleotides). Both
have a different set of fingers which allows searching and coding different ZF
modules as needed (40). The main advantage of this approach is that there is no
strict order to assemble the fingers and no selection step. This makes modular
assembly approach fast and less complicated. The context-dependent effect is the
only demerit associated with modular assembly.
A set of naturally occurring ZFs derived from human transcription factor
was found to recognize different triplet subsites (39). The DNA binding specificity
was determined using a yeast-based one-hybrid reporter molecule (42).
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3. Methyl Binding domain
Methyl binding domains (MBDs) are proteins that are capable of interpreting
DNA methylation signals of CpG. The structure of MBD in the complex is known to
fold into an /β sandwich structure which is composed of a layer of twisted β-sheets
backed by another layer of -helix and finally a hairpin loop at the C-terminus (25).
Methyl groups on the DNA are recognized by making major groove contacts by five
MBD residues Val-20, Arg-22, Tyr- 32, Arg-44 and Ser-45 (25). NMR studies and XRay images showed that the Arg-22 and Arg-44 are mainly involved in forming
hydrogen bonds with the guanine in the major grove (23). This pushes the guanine
residue towards the minor grove reducing the stacking interaction between the methyl
cytosine and the guanine. Agr residues also form a cationic -interaction with the
cytosine (43). The other residues are also involved in forming a hydrophobic patch
that helps in making contact with the mCG. Further specificity is provided by Try-34
residue owing to its hydroxyl side chain that is capable of accepting a hydrogen bond
from the 4-amino group of the mC (43). This was also proved by point mutation
analysis by changing the Tyr-34 with Phe or Ala (43). Replacement of Tyr-34 after
mutation did not show recognition of mCpG, indicating that Tyr-34 is important for
DNA binding. Mutation on Ser-45 also showed reduced DNA binding (43). Hence, it
could be concluded that the DNA binding to mCpG was a result of hydrophobic and
polar interactions of the five MBD residues on the major groove of methylated DNA.
The hairpin loop forms contacts with the DNA phosphodiester backbone which
favorably donates hydrogen bonds to anchor to the DNA at certain amino acid
residues (44).
The different methyl binding domains that are known to exist are MBD1, MBD2,
MBD4 and MeCP2 (23,45,46). However, all may not have methyl binding function
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in the mammalian system (47). MBD2 and MBD3 have an identical structure,
differing in the sizes of their introns and encode 70% of identical proteins. Yet,
mammalian MBD3 does not have methyl binding properties in humans (47). MBD2 is
a component of methyl-CpG binding protein 1 (MeCP1) complex. MeCP1 represses
transcription in a methylation density dependent manner (48). MBD1 contains a very
strong repression domain that is associated with recruitment of histone deacetylases
(23). Interestingly, the function of MBD4 is to minimize mutations by detecting
mismatches on the methyl-CpG in the genome, and like others it does not have a
repression domain (49).
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4. The mCpG SEER-LAC-Zinc Finger protein system
There are two main classes of engineered DNA-binding domains (DBD) - ZF
based DBD and transcription activator-like effector (TALE) DBD. The ZFP is
designed in such a way that it is capable of recognizing a specific DNA sequence. The
mCpG-SEER Lac system provides enzymatic amplification of a visual signal to
confirm the presence of the desired DNA sequence (36).
The SEER-Lac system depends on enzyme reassembly to recognize DNA
sequences. This system consists of a split protein system consisting of an enzyme
from TEM-1 β-lactamase and dissected into two halves, which are initially inactive,
but reassemble when they are brought in close proximity to form an active complex in
presence of a cognate DNA sequence. In nitrocefin assay, β-lactamase enzyme
hydrolyzes the β-lactam ring in the substrate, nitrocefin. When one of the spilt protein
is linked to a MBD protein and other to a ZF, upon activation of SEER-Lac system, a
desired methylated DNA sequence can be recognized (50). MBDs or mCpG site
enable the detection of aberrant methylation of tumor suppressor gene associated
promoter region on RASSF1A gene (51).
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LacA-ZFP immobilized on COC chip
DNA

DNA binding
Unbound molecule washing

Incubation with MBD-Lac B
Enzyme assay

Figure 6: mCpG-SEER-Lac system for ZFp array.
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5. Project Objectives
Since methylation occurs at a very primitive stage of cancer, early diagnosis of
methylation of the gene will help in disease management. With this technique, we can
develop a point of care testing that can easily detect the presence of methylated DNA
from the urine sample of a bladder cancer patient within 3-4 hours. It may be useful to
detect other carcinomas from the body fluids of the respective organ. This obviates
the need of a biopsy which is penetrative in nature and painful. Our initial goal was to
compare binding of target and non-target DNA using solution based assay. However,
a solution based assay showed less efficiency in differentiating the signals of target
and non-target due to the feasibility of the reaction provided by non-specific binding
to the DNA in case of some ZFPs. Hence, we used a ZFP array which allows washing
steps to wash away unbound proteins and DNA molecules from the cyclic olefin
copolymer chip (COC).
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CHAPTER 2
MATERIAL AND METHODS
1. Construction and expression of RASSF1A and MBD SEER proteins
All zinc finger proteins (ZFPs) were engineered using modular assembly from
Barbas domain in an Sp1framework. DNA recognizing regions for each ZFP were
commercially synthesized using BioBasic. ZFP (RASSF1A 150, RASSF1A 275,
RASSF1A 407, RASSF1A 686) were sub-cloned between XmaI and AgeI sites of
pMAL-c2X-Lac A stx2 268 by replacing the C terminal ZFP stx2-233-268. MBD2
and MBD1 was cloned between BamHI and AgeI sites of the pMaL-c2X stx2-233Lac B replacing the N-terminal ZFP with the MBD 2 or MBD1 domain. After the
plasmids were obtained, they were transformed into competent E.coli cells. DNA
from the cells were purified using the miniprep kit (Qaigen). Plasmid DNA
concentrations were measured using a Nanodrop (Thermoscientific). Approximately
3000 ng of plasmid DNA was used for restriction double digestion using XmaI and
AgeI and cut smart buffer. Digested DNA was analyzed on an agarose gel.
Desired vectors of pMAL-Lac A and pMAL Lac B (6.7 kb) and RASSF1A (540
bp) along with MBD1/2 (~207/231 bp) were isolated by cutting out from the agarose
gel, respectively and the DNA was extracted using gel extraction kit (Qaigen). Vector
and insert were ligated using T4 DNA ligase. However, pUC-SP MBD2 first had Lac
B inserted into it followed by insertion of MBD2-Lac B into pMAL vectors. The new
ligated plasmid was transformed in to 10 E.coli competent cells which were efficient
in replicating. These cells were verified for a size using a colony PCR. The same set
of colonies were also grown on a separate master plate and the LacA-RASSF1A and
MBD-Lac B were run in an agarose gel. Positive colonies were selected to be
transformed into protein expressing BL21 competent cells for protein expression.
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Table 2: Sequences of zinc fingers and their subsites.
ZFP

Finger 1

Finger 2

Finger 3

Finger 4

Finger 5

Finger 6

Target site

AAG

GGC

AAG

AGG

GGA

GAG

RASSF1A

RKDNLKN

DPGHLVR

RKDNLKN

RSDHLTN

DPGHLVR

RSDNLVR

Target site

GGG

GCT

CGC

GGG

GCT

CCC

RASSF1A

RSDKLVR

TSGELVR

HTGHLLE

RSDKLVR

TSGELVR

SKKHLAE

150

407

2. Cloning details
2.1 Miniprep- Plasmid isolation was achieved using a miniprep kit (Qaigen).
Cells were grown overnight in 5 mL LB broth/5 mM ampicillin. Cells
were centrifuged for 15 min at 4000 rmp at 4C. Supplier instruction
provided by the kit was followed. Exactly 30 L lukewarm water was
added to the column and allowed to sit at room temperature for 5 min. This
is to allow the DNA to dissolve in the water. The tubes were centrifuged
for 1 minute at 13,000 rpm at 4C and checked for the concentration of the
DNA.
2.2 Restriction digestion: 3000-3300 ng of all plasmid DNA were digested
with AgeI and XmaI (Lac A-RASSF1A). This was carried out in
duplicates or quadruplicates of the same sample. Similar amounts of MBD
plasmid DNA were digested with HindIII and AgeI. Double digestion was
performed using high fidelity restriction enzymes at 37C for 3 hours.
2.3 Gel separation: Digested DNAs of the zinc finger proteins were run on a
1.2% agarose gel (0.6 g agarose in 55 mL 1x TAE buffer- 40 nM Tris pH
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7.6, 20 nM acetic acid and 1 mM EDTA). Ethidium bromide was added to
the gel when gel solution becomes less warm. Restricted MBD DNAs
were run on a 1.8% gel. RASSF1A were cut ~540bp and MBD were cut
out at ~200-240 bp.
2.4 Gel extraction: The DNA gels were cut at their expected size and extracted
using the gel extraction kit (Qaigen). Supplier instrcutions were followed
to extract DNA from the gel. Exactly 22 L of lukewarm water was added
to the column. After 5 minutes, it was centrifuged for 1min at 13,000 rpm
at 4C.
2.5 DNA Ligation: All extracted DNA are to be plugged into a vector, pMALLac A or pMAL-Lac B. All ZF were to be inserted into pMAL-Lac AInsert and both MBD need to be inserted into pMAL-Insert-Lac B. NEB
T4 DNA ligase was used for ligation. The following vector and insert
ratios were used.
2.6 Transformation: New ligated plasmids were transformed into competent
NEB 10 E.coli cells. Competent cells were thawed at room temp on ice
for 10 min. Approximately 180 ng of plasmid DNA was added to the cells.
It was set on ice for 20 minutes followed by a heat shock treatment at 42
C for exactly 30 seconds and placed in ice immediately for 1 min. 350 L
of SOC medium of room temperature was added and the tubes were
allowed to shake for 1 hour at 37 C. This culture was spread on
LB/ampicillin plates. Plates were incubated at 37 C overnight for 12-16
hours.
2.7 Colony PCR: These colonies were analyzed for correct DNA insertion by
PCR amplification followed by running on an agarose gel. A portion of the
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colony was also dotted on a LB/Ampicillin plate (master plate). The
master plate is used as a reference for the positive colonies.
2.8 Transformation for protein expression: Positive colonies were transformed
into competent BL21 E.coli (Invitrogen) cells for protein expression as
explained earlier.
2.9 Protein purification: BL21 cells were cultured and induced with 0.3 M
Isopropyl β-D-1-thiogalactopyranoside (IPTG) at an OD600 of 0.6-0.8 for 3
hours at 37˚C. Cell pellets were stored in -80˚C prior to resuspension with
Zinc Buffer A ( ZBA: 100 mM Tris base, 90 mM KCl, 1 mM MgCl2 100
M ZnCl2 at pH 7.5) /5 mM dithiothreitol (DTT) and 50ug/RNAse A.
Cells were sonicated for 1 minute to lyse cells and was centrifuged to
collect the lysate. This was subjected to an amylose resin that as
equilibrated with ZBA and 5 mM DTT and washed with 2 M NaCl in ZBA
and 1 mM tris(2-carboxyethyl) phosphine (TCEP) and was finally eluted
in five 1ml fractions of 10 mM maltose and 1 mM TCEP in ZBA.
Concentrations of the purified proteins were analyzed using Bradford
assay and the purity of the purified proteins was verified using a
Coomassie stained sodium dodecyl polyacrylamide gel electrophoresis
(SDS-PAGE) using bovine serum albumin (BSA) as standards. Purified
proteins were stored on ice at 4˚C until utilized.
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3. DNA oligonucleotides
DNA oligonucleotides were designed to have methyl CpG on the sense strand
along with the ZFP target area on the anti-sense strand. Oligonucleotides were
annealed in a thermal cycler (BioRad, Hercules, California) using the following
protocol. Heat to 95˚C for 7 minutes, cool down to 56˚C and equilibrate at 56˚C for 5
minutes, cooling it further down to 25˚C and equilibrating at 25˚C for 10 minutes.
Table 3: List of oligonucleotides. Red color indicates methylatd target and purple color
indicates ZFP target
Oligonucleotide
Name
149 mCpG-2
149 CpG-2
407 mCpG
hairpin-3
407 CpG hairpin 3
149mCpG 3bp-3
149 CpG 3bp-3
149 mCpG 2bp-3
149 CpG 2bp-3
407 mCpG -4
407 CpG -4

Sequence (5'-3')
GCC TAmC GTA CTT GCC CTT CCT TCC CTC ACC G
CGG ATGmCAT GAA CGG GAA GGA AGG GAG TGG C
GCC TAC GTA CTT GCC CTT CCT TCC CTC ACC G
CGG ATG CAT GAA CGG CAA GGA AGG GAG TGG C
GCG TAmC GTA TGC CAG CTC CCG CAG CTC GGG TTT TCC CGA GCT GCG GGA GCT GGC ATA mCGT ACG C
CGC ATG CmAT ACG GTC GAG GGC GTC GAG CCC AAA AGG GCT CGA CGC CCT CGA CCG TAT GmCA TGC G
GCG TAC GTA TGC CAG CTC CCG CAG CTC GGG TTT TCC CGA GCT GCG GGA GCT GGC ATA CGT ACG C
CGC ATG CAT ACG GTC GAG GGC GTC GAG CCC AAA AGG GCT CGA CGC CCT CGA CCG TAT CCA TGC G

GTG ATG AGT GGA mCGA AGC TTG CCC TTC CTT CCC TCG ACG C
CAG TAC TCA CCT GmCT TCG AAC GGG AAG GAA GGG AGC TGC G
GTG ATG AGT GGA CGA AGC TTG CCC TTC CTT CCC TCG ACG C
CAC TAC TCA CCT GCT TCG AAC GGG AAG GAA GGG AGC TGC G
GTG ATG AGT GGA mCGA ACT TGC CCT TCC TTC CCT CGA CGC
CAC TAC TCA CCT GmCT TGA ACG GGA AGG AAG GGA GCT GCG
GTG ATG AGT GGA CGA ACT TGC CCT TCC TTC CCT CGA CGC
CAC TAC TCA CCT GCT TGA ACG GGA AGG AAG GGA GCT GCG
AGT CTA AGC TCA mCGT TTG CCA GCT CCC GCA GCT CCC ATC
TCA GAT TCG AGT GmCA AAC GGT CGA GGG CGT CGA GGG TAG
AGT CTA AGC TCA CGT TTG CCA GCT CCC GCA GCT CCC ATC
TCA GAT TCG AGT GCA AAC GGT CGA GGG CGT CGA GGG TAG

4. EMSA (Electrophoretic mobility shift assay)
Biotinylated EMSA oligonucleotides of concentration 20 M were annealed using a
thermal cycler (BioRad, Hercules, California) at conditions of heating to 95C for 3
minutes and cooling by 1C per 50 seconds to 4C. Equimolar concentrations of 100
M of forward and reverse oligo were diluted with 500nM NaCl/ water. ZFP solution
of desired concentrations was prepared using ZBA and 25% glycerol to the final
concentration. Annealed DNA was serially diluted from 20 M to 800 nM to 100 nM.
23

A pre-dilution mix was prepared using 150 mM KCl, 0.08% NP-40 detergent, 0.17
mg/mL BSA, 5 mM DTT and 0.83 nM annealed DNA. 3:2 proportion of pre-dilution
mix and 25% glycerol and 5mM DTT in ZBA, respectively. Further series of dilutions
of RASSF1A proteins and DNA were made from 1-10, in dilutions of 1:2 (in case of
Lac A-RASSF1A 407, starting from 200nM of protein) or 3:4 (in case of Lac ARASSF1A 150, starting from 800nM of protein). All 10 samples were run on a 10 %
polyacrylamide gel at 100 mV for 50 minutes. Transfer apparatus was used for the
transfer of protein-DNA bands on a nitrocellulose membrane. This process was run
for 1 hour at 100 mV. The nitrocellulose membrane was then cross-linked in a UVcross-linker for 4 minutes. Light shift EMSA kit (Pierce, Rockford, IL, USA) was
used according to kit’s instructions to block and wash the membrane.
5. Nitrocefin assay
A solution based assay of nitrocefin was assessed on purified proteins in a 96-well
plate and on a cyclic olefin copolymer chip (COC) was used for the array. In the
solution based assay, 20 L of the RASSF1A construct was added along with
equimolar concentrations of MBD1 or MBD2 construct in ZBA to make the final
volume 180 l. Different protein concentrations of 50, 125, 150, 200 and 250 nM
final concentrations of proteins were used to determine a dose response curve. 20 L
of different concentrations of 300, 200, 100, 50, 5, 20, 10 and 1 nM of the
oligonucleotides were added to the 96-well plate. Combinations of RASSF1A was
used with MBD 1 and MBD2. After incubation for 1 hour, 20 L of nitrocefin
(Calbiochem) was added right before reading its absorbance in at 486 nM in a
spectrophotometer (Molecular devices Sunnyvale, CA).
For reading ZFP array, DNA oligonucleotides were annealed using the
protocol described above. ZFP immobilization and reaction area was confined using a
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silicone gasket (Grace-biolab) providing an area with a diameter of 6 mm and a depth
of 1mm. 5.3ul of purified MBP-Lac A-ZFP (RASSF1A) of the concentration of 2.5
M was immobilized on the hydrophobic surface and incubated for 60-90 minutes
until solution dries. Exactly 10 l of DNA of different concentrations were added to
different wells and allowed to bind for 20 minutes. The gasket was removed before
washing the slide with ZBA/50 mM KCl followed by ZBA/ 0.05% Tween-20. 10 l
of 2.5 M of purified MBD1 or 2-Lac B was added and incubated for 20 minutes to
allow coupling with methylated DNA and RASSF1A protein.
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CHAPTER 3
RESULTS AND DISCUSSION
1. Colony PCR results
Gel pictures of agarose gel stained with ethidium bromide were taken using a
gel imager. In figure 6, the bright spots at ~ 700 bp indicated positive colonies
for MBD1-Lac A and MBD2-Lac B. Positive colonies for Lac A-RASSF1A
150, Lac- RASSF1A 275, Lac- RASSF1A 407 and Lac- RASSF1A 686 in
figure 7 were observed at ~1.2 kp. Positive colonies on the master plate were
used for protein expression and purification.
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Figure 7: Gel image from colony PCR results of pMAL-MBD1-Lac B and pMALMBD2-Lac B. Lane 1 is the NEB 1 kb Ladder. Red/ black box indicates positive
colonies at ~700 kb. Lane 10 is NEB 100 bp ladder.
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Figure 8: Gel image from colony PCR results of Lac A-RASSF1A 150, Lac ARASSF1A 275, Lac A-RASSF1A 407 and Lac A-RASSF1A 686 (from left to right).
Lane 1 is the 10 kb or 100 bp. Red box indicates positive colonies at ~1.2 kb.
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2. SDS-PAGE gel
Purified proteins were subjected to SDS-PAGE to check purity of the protein
on the basis of separation from other proteins. In all gels, the first lane was a protein
standard for reference. Lanes 2-5 were the mixture of proteins in the washing
solutions from the purification steps. Lane 6-10 were the proteins of interest eluted
with a 10 mM maltose solution from the amylose resin. These lanes look free from
other proteins. Both MBD1-Lac B and MBD2-Lac B were observed near 62.5 kDa
and both Lac A-RASSF1A-150 and Lac A-407 were observed at around 84 kDa.
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Figure 9: SDS gel picture of MBD1-Lac B and MBD2-Lac B (left to right). Red box
indicates presence of protein MBD1-Lac B and MBD2-Laac B at ~62.5 kDa.
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Figure 10: SDS gel picture of Lac A-RASSF1A 150 and Lac A-RASSF1A 407 (left
to right). Red box indicates presence of protein Lac A-RASSF1A 150 and Lac ARASSF1A407 at ~84 kDa.
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3. Electrophoretic mobility shift assay (EMSA)
Binding affinity can be determined from the bands that yield approximately
equal association and dissociation of the protein-DNA complex. Our EMSA
results suggests that RASSF1A 407 shows binding affinity of 4.86 nM and
binds to its cognate DNA sequence very strongly. However, the binding affinity
of RASSF1A 150 was found to be 253.1 nM, indicating a weaker binder than
RASSF1A 407.
Units- nM

200

100

50

25

12.5

6.25.

3.12

1.06

0.03

0

a

Units- nM

800

600
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337.5

253.1

189.8

142.3

106.7

80.0

0

b

Figure 11: EMSA results of protein Lac A-RASSF1A 407 (a) and Lac ARASSF1A 150 (b). Figures on the top indicate the protein concentration in nM
and red rectangles indicate the kd value.
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4.

Experiments from solution based nitrocefin assay

Table 4: Sets of experiments in solution based assay
#

1

2

ZFP

Lac

MBD

A-

MBD1-

RASSF1A 150

Lac B

Lac

MBD1-

A-

RASSF1A 686

Protein

DNA

Oligonucleotide

concentration

concentration

sequence #

(nM)

(nM)

145

200,100,50,20

149 mCpG-2
149 CpG-2

125

100, 50

Lac B

661

mCpG

hairpin-2
661
hairpin-2
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CpG

Lac A-RASSF1A 150 and MBD1-Lac B
(145 nM after 60 minutes)
0.7

Absorbance at 486 nm

0.6
0.5
0.4
mCpG
0.3

CpG

0.2

0.1
0
200 nM 100 nM

50 nM

20 nM

No DNA Substrate

Figure 12: Nitrocefin assay using Lac A-RASSF1A 150 and MBD1-Lac B of
concentration 145 nM with DNA concentration 200, 100, 50, 20 nM.

Lac A-RASSF1A 686 and MBD 1-Lac B
(125 nM after 30 minutes)
0.7

Absorbance 486 nm

0.6
0.5
0.4
mCpG
0.3

CpG

0.2
0.1
0
100 nM

50 nM

10 nM

5 nM

No DNA Substrate

Figure 13: Nitrocefin assay using Lac A-RASSF1A 686 and MBD1-Lac B of
concentration 125 nM with DNA concentration 100, 50, 10, 5 nM.
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From the above sets of solution based nitrocefin assays, following observations were
made as per each protein:
Lac A-RASSF1A 150
This ZFP did not show any qualitative signals for binding in the solution based
assay. It was observed that increasing DNA concentration also did not improve in the
signals and increasing protein concentration was also not very useful. It is unclear
why higher signals were not observed by increasing protein concentrations.
Lac A-RASSF1A 686
Although this construct gave the highest signals for non-specific binding, the
assay revealed some details of MBD’s specificity by showing lower signals for 5 nM
CpG and higher for mCpG. Lowering DNA and protein concentration did not have
any affect on lowering the signals. Oligonucleotides having the mCpG group showed
an unexpected lowering in signals. We could speculate that hairpin DNA
oligonucleotides showed the lowest signals because their structure pushed the target
and mCpG site far from each other, making it difficult for the split Lac domains to
reassemble. It was predicted that mCpG should be positioned on the sense strand of
the DNA while ZF target should be positioned on the anti-sense strand because when
both mCpG and ZFP target site are on the sense strand, coiling of the DNA might
push the target side away and on the other side of the DNA, causing Lac A and Lac B
to be distant. Target sequence on the anti-sense strand could ensure that the target
falls on the same side as the mCpG group, making it easier for the split Lac domains
to reassemble. It is necessary that both mCpG and target site fall in the major groove
of the DNA. The proteins are relatively larger in size and need more space to get
accommodated. The major groove provides ample space for split Lac domain
reassembly and protein-DNA binding. Our data suggests that hairpin DNA structures
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also have a tendency to increase the distance between mCpG and target site. In some
cases, non-methylated oligonucleotides also show signals due to self-reassembly of
Lac A and Lac B.

Our results suggest inefficiency of the solution based assay to be caused by
background signals due to the self-reassembly of Lac A and Lac B at high protein
concentrations. Therefore, we implemented another method by making use of a
protein array on the surface, which would allow for removal of unbound and weakly
bound molecules.
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5. Experiments from zinc finger protein array
Table 5: Set of experiments from the ZFP array
Assay #

1.

Lac A-ZFP

MBD-Lac

DNA

Oligonucleotide

protein

B protein

concentration

sequence #

2.5 M

2.5 M

(nM)

RASSF1A

MBD1

250, 50, 10

150
2.

RASSF1A

149 mCpG 2bp-3
149 CpG 2bp-3

MBD1

250, 10

150

149 mCpG 3bp-3
149 mCpG 3bp-3
149 mCpG 2bp-3
149 CpG 2bp-3

3.

b

4.

a

RASSF1A

MBD1

150

MBD2

RASSF1A

MBD 1

150

MBD 2

RASSF1A

MBD1

407

MBD2

250, 50, 10

149 mCpG 2bp-3
149 CpG 2bp-3

250, 50 ,10

149 mCpG 3bp-3
149 mCpG 3bp-3

50,10

402 mCpG- 4
402 CpG- 4
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0.7
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0.4
mCpG
0.3

CpG

0.2
0.1
0
250 nM

50 nM

10 nM

No DNA Substrate

Figure 14: Nitrocefin assay using Lac A-RASSF1A 150 and MBD 1-Lac B at protein
concentration of 2.5 M. Determination of DNA binding at different DNA
concentrations. (Assay 1)
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0.7

Absorbance at 486 nM

0.6
0.5
0.4
0.3

mCpG
CpG
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0.1
0
250 nM

10 nM

2bp
oligonucleotides

250 nM

10 nM

No DNA Substrate

3bp oligonucleotides

Figure 15: Nitrocefin assay for signal comparison of 2 bp and 3 bp spacing
oligonucleotides with concentrations of 250 and 10 nM, using Lac A-RASSF1A 150
and MBD1-Lac B. (Assay 2)
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50n M

MBD1
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Figure 16: Nitrocefin assay show comparison of MBD 1 and MBD 2 with Lac ARASSF1A 150 with oligonucleotides of 2 bp spacing. Proteins are of the
concentration 250 nM. (Assay 3a)
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Figure 17: Nitrocefin assay showing comparison of MBD 1 and MBD 2 with Lac ARASSF1A 150 with oligonucleotides of 3 bp spacing. Proteins are of the
concentration 250 nM. (Assay 3b)
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Figure 18: Nitrocefin assay showing comparison of MBD 1 and MBD 2 with Lac ARASSF1A 407 and DNA concentration of 50 and 10 nM. (Assay 4)
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Assay 1
Lac A- RASSF1A 150 in figure 15, shows dose dependent signal with MBD1-Lac
B at protein concentration 2.5 M and oligonucleotide concentrations of 250, 50, and
10 nM. This suggests that ZFP RASSF1A 150 has high selectivity for the system.
MBD1 being a strong repressor of the methylated DNA, binds tightly and specifically
to the methylated target. The position of mCG and ZFP target is most suitable in this
case, showing great signal difference between methylated and non-methylated DNA.
Low signals for substrate alone and DNA suggest low background.
Assay 2
Two oligonucleotides with different spacing between mCpG and ZF target were
used. One was positioned 2 bp apart and the other was 3 bp apart. The results from
figure 16 suggested that 2 bp shows higher efficiency than 3 bp, probably owing to
the fact that it is situated closer to the axis of the DNA double helix resulting in more
space to allow effective reassembly of Lac A and Lac B. Even though the difference
in space for 2 bp and 3 bp is not as much, a difference in 1 bp near the vertices of the
double helix may result in a relatively big difference in the position of the ZFP target.
This may hinder the spontaneous association of Lac A and Lac B due to their
geometric conformation and location. DNA concentrations of 250 nM and 10 nM
show accurate difference in signal between methylated DNA and non-methylated
DNA as well as lower signals for the 3 bp oligonucleotide DNA.
Assay 3a, 3b, and 4
From figures 17 and 18, the two different oligonucleotides mentioned above
were checked for signals using both MBD1 and MBD2 proteins. In the case of
RASSF1A 150, in both instances, MBD1 showed more effective binding results in the
mCpG-SEER-Lac system. However, from figure 18 we observed that MBD2 shows
higher signals than MBD1 in the mCpG SEER Lac system with RASSF1A 407.
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MBD1 and MBD2 are the only methyl binding domains that respond to methylated
DNA (51). In our system, both MBD1 and MBD2 were capable of differentiating
methylated target from non-methylated target.

41

Effects of oligonucleotide structure on the assay
The oligonucleotides first designed were 31 bp long and had both the methyl cytosine
and target on the sense strand. It can be inferred that when the target is on the
antisense strand, the helix formation would cause the target and the methyl cytosine
(mC) to fall in the major groove. If the opposite was the case, then the target and mC
would be farther away from each other and one of them would fall in the minor
groove. This distancing would make it impossible for the Lac A and Lac B to
reassemble upon binding of MBD and ZFP. The length of the oligonucleotide may
change the origin of the helix and cause the mC to fall in the minor groove, possibly
preventing MBD from binding to mCG. Since arginine in MBD makes contacts with
G via two hydrogen bonds and hydrophobic interaction with G, it is a primary
requirement that mC should be accompanied with a G (43). Lastly in figure 18, we
designed a 39 bp oligonucleotide, with the first 12 bp of random sequence followed
by mC. After leaving a 2-3 bp spacing, the target was placed on the anti-sense strand.
Starting with a 12 bp random sequence ensures completion of one turn of the DNA
double helix. We could hence assume that the mC and target site fall in the major
groove. Our data also suggests that 2 bp spacing provides favorable space and
reduction in distance between Lac A and Lac B, so they reassemble more efficiently
than 3 bp spacing.
Other factors that could influence successful discrimination between
methylated and non-methylated oligonucleotide are the binding incubation time and
washing steps involved in the ZFP array. Immobilization of the ZFP on the cyclic
olefin copolymer (COC) chip via hydrophobic interactions confirms accessibility of
ZFPs. Incubation time for DNA binding allows protein-DNA interaction to take place.
ZFPs binds to its target site and unbound DNA washes off in the washing step. This
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gives a clear stage for MBD to bind to the DNA which is already bound to the ZFP on
its target site. Simultaneous binding of MBD and ZFP to DNA leads to reassembly of
Lac A and Lac B. ZFP array allows binding of the ZFP and MBD to cognate DNA. In
case of a non-methylated DNA, the ZFP array will allow binding of ZFP to target but
will wash away the unbound MBD, resulting in relatively low signal.

12 3 4 5 6

8 9 10 1112 13 141516 17181920 21222324

mCG

mCG
1 2 3 4 5 6 7 8 9 10 1112 13 141516 17181920 21222324

mCG
Figure 19: Oligonucleotide sequence highlighting methylated CG dinucleotide (mCG)
(red) and ZFP target (blue).
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CHAPTER 4
CONCLUSION
In conclusion, mCpG SEER-Lac system is an efficient system to detect a
desired methylated DNA. The idea of using MBD proteins serves as an excellent
detector system that binds to the mCpG on the DNA (51). However, the solution
based assays from figures 12 and 13, did not show any signal difference between
methylated and non-methylated DNA. It also did not reveal any dose dependent
signals. This encouraged us to implement the use of a hydrophobic COC chip based
nitrocefin assay. Immobilization of the ZFP and sufficient incubation time for DNAZFP binding allows elimination of unbound DNA and availability of ZFP-DNA
complex. This makes it easy for the MBD to find the methylated DNA and bind to it.
ZFP array shows a great difference in signal between methylated and non-methylated
DNA. Figure 14, 15 and 17 show a dose dependent signal for methylated target.
Signals for reactions without target DNA were also reduced. This diminishes the
probability of false positives. These effects can be explained on the basis of the
geometry attained by the DNA after binding with the ZFP and position of the target
and methyl. The key idea was to make enough space in the major groove of the DNA
to allow binding of both MBD on the mCpG and ZFP on its target. Simultaneous
binding allows Lac A and Lac B to be positioned in close proximity facilitating
activation on reassembly of the two inactive fragments. This assumption was
corroborated by the results from assay 2 in figure 15, where, the ZF target was placed
with a 2 bp spacing next to the mCG in the oligonucleotides. Results from the 3 bp
oligonucleotide could be lower because of increase in the distance between mCpG
and ZF target. In the 39 bp oligonucleotide described earlier, it is possible that the
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target gets positioned at the center of the loop (or towards the end of the major
groove) making it difficult for the LacA and Lac B to reassemble.
MBD1 and MBD2 both show binding to mammalian mCpG (47). However,
many other experiments also suggest that MBD1 and MBD2 show higher preference
for mCpG than other methyl binding proteins (51). This was the reason for selection
of MBD 1 and MBD2 proteins in our assay. Our results from figures 16 and 17
suggest that both MBD1 and MBD2 are specific in the mCpG SEER-Lac system in
binding to its methylated target sequence. Since both ZFPs have 3 GNN targeting ZF
modules in their structures, both share a distributed sense of binding across the
cognate DNA sequence. EMSA results from figure 11 also suggest that both
RASSF1A 150 and 407 show good binding affinity towards their target confirming
the intensity of signals obtained. Large signal difference in the methylated and nonmethylated DNA show that the system is effective in detection of methylated DNA
and reduces the risk of attaining false positives. Rectification of this error makes
mCpG- SEER Lac a better detection system than other methylation detection system
like Bisulfite sequencing.
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CHAPTER 5
FUTURE DIRECTION
Detection of cancer at the early stage is very important to help in prognosis. Cancer
biomarkers are the most suitable target for detection of cancer. In case of bladder
cancer, a panel with RASSF1A, APC and p14 serves as a reliable set of biomarkers to
detect bladder cancer in urine (29,52). Efficiency of such panels with combination of
different biomarkers have been studied using other methods (29). Our approach enables
us to detect specific DNA sequences in the RASSF1A for bladder cancer. A point ofcare device could be developed with custom designed ZFP targeting specific regions in
multiple genes of a cancer biomarker. Other biomarkers related to the same cancer can
also be tested alongside. This panel for detection of different cancer biomarkers may
provide information needed to indicate the presence of a tumor. There are biomarkers
which can be detected in the body like fluid blood or urine from concerned tissue (27).
This diagnostic test is more beneficial over a penetrative procedure to obtain biopsy
material for the detection of cancer.
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ABBREVIATIONS
1. ZFP- Zinc Finger Protein
2. TSG- Tumor suppressor gene
3. RASSF1A- Ras- associated family 1 subfamily A
4. Nore1a- RASSF1A homolog
5. SARAH- sav/RASSF/Hpo domain
6. CpG- Cytosine Guanine dinucleotide
7. mCpG- methylated cytosine guanine dinucleotide
8. GTPase- guanosine triphosphatase
9. PMCa- plasma membrane calcium ATPase
10. MOAP-1- Modulator of apoptosis 1
11. SAV- Salvador protein
12. LATs ½- Linker for activation of T-cells
13. MST1- Macrophage stimulating 1 protein
14. CNK1- Connector enhancer of kinase suppressor of RAS 1
15. BAX- BCL2- Associated X protein
16. MAP18- Microtubule associated protein
17. APC- Adenomatous polyposis coli
18. JNK- c-Jun-NH2-Kinase
19. TNFR- Tumor necrosis factor receptor
20. DNMT- DNA methyltransferase
21. MBD- Methyl binding domain
22. Val- valine
23. Arg- Arginine
24. Tyr- Tyrosine
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25. Ser- Serine
26. NMR- Nuclear magnetic resonance
27. Phe- Phenyl alanine
28. Ala- Alanine
29. DBD- Dna Binding domain
30. SEER- Sequence Enabled reassembly
31. IPTG- Isopropyl β-D-1-thiogalactopyranoside
32. ZBA- Zinc buffer A
33. TCEP- tris(2-carboxyethyl) phosphine
34. DTT- dithiothreitol
35. NaCl- Sodium chloride
36. BSA- Bovine serum albumin
37. COC- Cyclic olefin copolymer
38. nM- nanomolar
39. nm- nonometers
40. l- microliter
41. M- micromolar
42. C- Degree centigrade
43. bp- basepair
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